CardioVascular BioTherapeutics Inc. to Present at the Jefferies Life Sciences Conference.LAS VEGAS -- CardioVascular BioTherapeutics Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT CVBT Cardiovascular Biotherapeutics, Inc CVBT Central Virginia Battlefields Trust (Fredericksburg, VA Civil War history organization) ) announced today that Daniel C. Montano, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , has been invited to present at the Jefferies Life Sciences Conference. The event will take place on June 27 and June 28 at the Mandarin Oriental New York Hotel. Montano commented, "I am very excited to showcase the great strides CVBT has made as we continue to pursue the many different applications of Cardio Vascu-Grow(TM). The Jefferies Life Sciences Conference is a fantastic opportunity to present our accomplishments to investors and the medical community alike." CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. in no-option heart patients, and one in impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the United States. A foreign proof of concept clinical trial has been initiated in chronic back pain, where restricted blood supply to the lower back has been implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in this common ailment. This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our expectations for new research, our progress with clinical trials or our future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of our drug candidates, market acceptance of CardioVascular BioTherapeutics Inc. products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission. Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion